The Role of MRD in Hematologic Malignancies

Slides:



Advertisements
Similar presentations
STATUS OF DETECTION OF MINIMAL
Advertisements

Minimal Residual Disease in Hematologic Neoplasms Lloyd M. Stoolman, M.D. Professor of Pathology and Director, Clinical and Research Flow Cytometry Laboratories.
Adult ALL – therapeutic strategies, including Burkitt
Cytogenetic and molecular diagnostic characterization combined to postconsolidation minimal residual disease assessment by flow cytometry improves risk.
9 Chapter Nine Neoplasms. © 2013 The McGraw-Hill Companies, Inc. All rights reserved. Learning Outcomes After completing this chapter, you will be able.
Current Uses and Outcomes of Hematopoietic Stem Cell Transplantation 2011 Summary Slides Worldwide SUM-WW11_1.ppt.
Conclusions We have developed a robust, quality controlled, sensitive method for MRD assessment in precursor B cell ALL which can be replicated in a multi.
A Novel Approach for Unique MRD Markers Identification in Acute Leukemia Patients Tereza Jančušková synlab genetics s.r.o. Evropska 176/16, Prague, Czech.
Hematology and Hematologic Malignancies
Acute Leukemia Kristine Krafts, M.D..
Value of MRD to Predict PFS in MM: Results From IFM/DFCI 2009
Date of download: 7/2/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Genome-wide Interrogation of Germline Genetic Variation.
AIMING FOR EXCELLENCE IN OUTCOMES IN HAEMATOLOGIC MALIGNANCIES Taking a Deeper Approach to Multiple Myeloma Treatment UK/NP/1508/0047c(1) April 2016 A.
MRD testing: which platforms, which patients?
Acute Leukemia Kristine Krafts, M.D..
Distribution of diagnoses among the nearly 115,000 cases of lymphoid malignancy diagnosed in There are 5400 cases of acute lymphoid leukemia (ALL),
Distribution of diagnoses among the nearly 115,000 cases of lymphoid malignancy diagnosed in There are 5400 cases of acute lymphoid leukemia (ALL),
Blinatumomab After AlloHSCT in Patients With R/R B-Precursor ALL
IFM/DFCI 2009 Trial: Autologous Stem Cell Transplantation (ASCT) for Multiple Myeloma (MM) in the Era of New Drugs Phase III study of lenalidomide/bortezomib/dexamethasone.
Slide set on: McCarthy PL, Owzar K, Hofmeister CC, et al
Minimal Residual Disease (MRD) Detection Technologies
Evaluation of Minimal Residual Disease by Real-Time Quantitative PCR of Wilms’ Tumor 1 Expression in Patients with Acute Myelogenous Leukemia after Allogeneic.
Image 1 Detection of minimal residual disease (MRD) in consecutive bone marrow (BM) samples from a patient with relapse (A) and a patient still in remission.
Pharmacy Perspectives in Multiple Myeloma: Relapsed and/or Refractory Disease.
MRD in Myeloma: the Future is Here
Acute Heart Failure.
Updates in Hodgkin Lymphoma
Pharmacogenetics of minimal residual disease response in children with B-precursor acute lymphoblastic leukemia: a report from the Children's Oncology.
The Role of MRD in Hematologic Malignancies
A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.
Donor Lymphocyte Infusion for Relapsed Hematological Malignancies after Allogeneic Hematopoietic Cell Transplantation: Prognostic Relevance of the Initial.
Acute leukemia: A pediatric perspective
Treating Transplant-Ineligible Patients With Multiple Myeloma
Goals of Therapy in Relapsed CLL
Multicolor Flow Cytometry and Multigene Next-Generation Sequencing Are Complementary and Highly Predictive for Relapse in Acute Myeloid Leukemia after.
Olga Sala Torra, Megan Othus, David W
Global Burden of VTE. Preventing Thrombosis During and Post-Hospitalization: New Paradigms in Clinical Care.
Volume 14, Issue 3, Pages (March 2013)
Volume 15, Issue 8, Pages (July 2014)
Management Challenges in CLL
Practical Guidance on Using New Therapies for Relapsed/ Refractory Follicular Lymphoma and Chronic Lymphocytic Leukemia.
Molecular Classifiers for Prediction of Minimal Residual Disease (MRD) and Event Free Survival (EFS) Improve Risk Assignment at Diagnosis in Pediatric.
by Jayesh Mehta Blood Volume 112(2): July 15, 2008
First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome–positive (Ph+) acute lymphoblastic.
Accurate quantification of minimal residual disease at day 15, by real-time quantitative polymerase chain reaction identifies also patients with B-precursor.
Residual Cancer Lymphocytes in Patients With Chronic Lymphocytic Leukemia After Therapy Show Increased Expression of Surface Antigen CD52 Detected Using.
Minimal Residual Disease in CLL
Accurate Sample Assignment in a Multiplexed, Ultrasensitive, High-Throughput Sequencing Assay for Minimal Residual Disease  Jack Bartram, Edward Mountjoy,
Personalized Therapy in Relapsed or Refractory CLL
Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children’s Oncology Group study AALL0232 by Michael J. Borowitz,
Figure 1 The dynamic nature of resistance mechanisms can be
Staying Abreast of Best Practices Across the Clinical Continuum
Qualitative and quantitative PCR monitoring of minimal residual disease (MRD) in relapsed poor-risk chronic lymphocytic leukemia (CLL): early assessment.
Managing Patients with Relapsed CLL who Discontinue BCR Signaling Inhibitors.
New ELN Recommendations
Donor Lymphocyte Infusion for Relapsed Hematological Malignancies after Allogeneic Hematopoietic Cell Transplantation: Prognostic Relevance of the Initial.
Unrelated Cord Blood Transplantation in Adult and Pediatric Acute Lymphoblastic Leukemia: Effect of Minimal Residual Disease on Relapse and Survival 
First-Line FCR: Effect of del(17p) on PFS and OS
Unrelated Donor Allogeneic Hematopoietic Cell Transplantation Is Underused as a Curative Therapy in Eligible Patients from the United States  Song Yao,
The Role of Measurable Residual Disease in AML
Allogeneic Transplantation for Pediatric Acute Lymphoblastic Leukemia: The Emerging Role of Peritransplantation Minimal Residual Disease/Chimerism Monitoring.
Immunoglobulin and T Cell Receptor Gene High-Throughput Sequencing Quantifies Minimal Residual Disease in Acute Lymphoblastic Leukemia and Predicts Post-
Residual Cancer Lymphocytes in Patients With Chronic Lymphocytic Leukemia After Therapy Show Increased Expression of Surface Antigen CD52 Detected Using.
Minimal Residual Disease and Hematologic Malignancies
MRD Analysis in Chronic Lymphocytic Leukemia
Overall survival among children with acute lymphoblastic leukemia who were enrolled in Children's Cancer Group and Children's Oncology Group clinical trials,
by Monika Brüggemann, and Michaela Kotrova
Minimal Residual Disease in Multiple Myeloma
Utilizing MRD Assessment in Community Practice
Presentation transcript:

The Role of MRD in Hematologic Malignancies

Educational Objectives

Minimal Residual Disease

Minimal Residual Disease (cont)

Flow Cytometry

MRD Sensitivity Using Flow Cytometry By Disease State

Genetic Methods for MRD Quantification

Genetic Methods for MRD Quantification (cont)

Genetic Methods for MRD Quantification (cont)

Allele-Specific Oligonucleotide (ASO)-PCR

MRD Methods – Next Generation Sequencing

MRD Methods -- Next Generation Sequencing (cont)

MRD Methods -- Next Generation Sequencing (cont)

MRD Methods -- Next Generation Sequencing (cont)

ASO-PCR vs NGS

Comparison of MRD Assessment Approaches

Current Role of MRD Assessment in Clinical Care

MRD in Acute Lymphoblastic Leukemia Children's Oncology Group AALL0232

COG AALL0232: Outcomes

ALL: Outcomes by Quantitative MRD Ranges

MRD Following HCT in ALL

Post-Transplant MRD in CLL

MRD and Outcomes in MM

MRD in Non-Hodgkin Lymphoma

Summary of MRD in Lymphoid Malignancies

Future Perspectives in MRD

Abbreviations

Abbreviations (cont)